Wall Street analysts predict that Dynavax Technologies Co. (NASDAQ:DVAX) will announce earnings per share of ($0.34) for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Dynavax Technologies’ earnings. The highest EPS estimate is ($0.33) and the lowest is ($0.37). Dynavax Technologies posted earnings per share of ($0.64) in the same quarter last year, which indicates a positive year over year growth rate of 46.9%. The firm is expected to report its next earnings results on Tuesday, February 25th.
On average, analysts expect that Dynavax Technologies will report full year earnings of ($2.04) per share for the current financial year, with EPS estimates ranging from ($2.08) to ($2.00). For the next fiscal year, analysts expect that the firm will post earnings of ($1.04) per share, with EPS estimates ranging from ($1.11) to ($0.90). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side analysts that follow Dynavax Technologies.
Dynavax Technologies (NASDAQ:DVAX) last posted its earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.40) by ($0.10). The firm had revenue of $10.58 million during the quarter, compared to analyst estimates of $10.31 million. Dynavax Technologies had a negative net margin of 519.95% and a negative return on equity of 399.60%. Dynavax Technologies’s revenue for the quarter was up 624.7% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.65) EPS.
A number of equities research analysts recently issued reports on the company. HC Wainwright reissued a “buy” rating on shares of Dynavax Technologies in a research report on Thursday, November 7th. William Blair reissued a “buy” rating on shares of Dynavax Technologies in a research report on Friday, January 3rd. Zacks Investment Research downgraded Dynavax Technologies from a “hold” rating to a “sell” rating in a research report on Monday. ValuEngine raised Dynavax Technologies from a “hold” rating to a “buy” rating in a research report on Friday, January 3rd. Finally, BidaskClub raised Dynavax Technologies from a “hold” rating to a “buy” rating in a research report on Wednesday. One research analyst has rated the stock with a sell rating and seven have given a buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $12.63.
Several hedge funds have recently modified their holdings of DVAX. Marshall Wace LLP boosted its holdings in shares of Dynavax Technologies by 225.0% in the 1st quarter. Marshall Wace LLP now owns 16,449 shares of the biopharmaceutical company’s stock valued at $120,000 after purchasing an additional 11,387 shares in the last quarter. Swiss National Bank lifted its stake in shares of Dynavax Technologies by 4.2% in the 2nd quarter. Swiss National Bank now owns 119,078 shares of the biopharmaceutical company’s stock valued at $475,000 after acquiring an additional 4,800 shares during the last quarter. Bank of Montreal Can lifted its stake in shares of Dynavax Technologies by 148.4% in the 2nd quarter. Bank of Montreal Can now owns 7,440 shares of the biopharmaceutical company’s stock valued at $29,000 after acquiring an additional 4,445 shares during the last quarter. M&T Bank Corp lifted its stake in shares of Dynavax Technologies by 29.5% in the 2nd quarter. M&T Bank Corp now owns 13,685 shares of the biopharmaceutical company’s stock valued at $54,000 after acquiring an additional 3,116 shares during the last quarter. Finally, Renaissance Technologies LLC bought a new position in shares of Dynavax Technologies in the 2nd quarter valued at $747,000. 82.40% of the stock is currently owned by hedge funds and other institutional investors.
Shares of NASDAQ:DVAX opened at $6.05 on Thursday. The company has a market capitalization of $507.35 million, a P/E ratio of -2.37 and a beta of 0.59. Dynavax Technologies has a 1 year low of $2.60 and a 1 year high of $12.42. The company has a debt-to-equity ratio of 5.48, a current ratio of 4.94 and a quick ratio of 4.09. The business’s 50 day simple moving average is $6.07 and its 200 day simple moving average is $4.63.
Dynavax Technologies Company Profile
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older.
Featured Article: Outstanding Shares, Buying and Selling Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.